Tango Therapeutics Inc. Insider Trading

TNGX

Last 12 months

Insiders sold $7.96M and bought nothing on the open market.

91% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Nov 2024.

Net open-market

−$7.96M

0 buys · 17 sales

Under a 10b5-1 plan

91%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Nov 2024

Nov 18, 2024

Get an email when TNGX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2	Adam Crystal President, R&D	Sold10b5-1 plan 2 parts	5,000	$22.42 average	112K	4.1%	Form 4
Nov 2	Jessica Newcomb Principal Accounting Officer	Sold10b5-1 plan 2 parts	7,031	$22.42 average	158K	12%	Form 4
Oct 1	Adam Crystal President, R&D	Sold10b5-1 plan 2 parts	27,000	$24.47 average	661K	19%	Form 4
Sep 22	Jessica Newcomb Principal Accounting Officer	Sold10b5-1 plan 3 parts	8,200	$24.22 average	199K	12%	Form 4
Sep 1	Adam Crystal President, R&D	Sold10b5-1 plan	27,000	$22.37	604K	19%	Form 4
Aug 3	Adam Crystal President, R&D	Sold10b5-1 plan 2 parts	27,000	$27.24 average	736K	19%	Form 4
Jul 1	Adam Crystal President, R&D	Sold10b5-1 plan 2 parts	27,000	$29.59 average	799K	19%	Form 4
Jun 1	Adam Crystal President, R&D	Sold10b5-1 plan 2 parts	27,000	$22.88 average	618K	19%	Form 4
May 1	Adam Crystal President, R&D	Sold10b5-1 plan 2 parts	27,000	$21.22 average	573K	19%	Form 4
Apr 15	Adam Crystal President, R&D	Sold10b5-1 plan	38,460	$25.00	962K	25%	Form 4
Apr 1	Adam Crystal President, R&D	Sold10b5-1 plan	27,000	$21.20	572K	19%	Form 4
Mar 25	Adam Crystal President, R&D	Sold10b5-1 plan	12,000	$20.11	241K	9.6%	Form 4
Mar 5	Adam Crystal President, R&D	Sold10b5-1 plan	20,251	$15.00	304K	15%	Form 4
Feb 25	Adam Crystal President, R&D	Sold10b5-1 plan	54,345	$12.77	694K	29%	Form 4
Feb 3	Daniella Beckman Chief Financial Officer	SoldNo plan 2 parts	10,317	$12.27 average	127K	5.3%	Form 4
Feb 3	Barbara Weber Director, Executive Chair	SoldNo plan 2 parts	30,519	$12.27 average	374K	1.8%	Form 4
Feb 3	Adam Crystal President, R&D	SoldNo plan 2 parts	18,452	$12.27 average	226K	9.0%	Form 4
Oct 23, 2025	TRV GP IV, LLC Large holder	SoldNo plan	477,401	$10.15	$4.85M	3.4%	Form 4
Sep 25, 2025	TRV GP IV, LLC Large holder	SoldNo plan	500,000	$8.02	$4.01M	3.5%	Form 4
Sep 16, 2025	TRV GP IV, LLC Large holder	SoldNo plan	363,541	$7.04	$2.56M	2.5%	Form 4
Sep 5, 2025 – Sep 8, 2025	TRV GP IV, LLC Large holder	SoldNo plan 2 parts	729,365	$7.00 average	$5.11M	4.7%	Form 4
Aug 22, 2025	Third Rock Ventures GP IV, L.p. Large holder	SoldNo plan	302,194	$7.00	$2.12M	1.9%	Form 4
Aug 19, 2025	Third Rock Ventures GP IV, L.p. Large holder	SoldNo plan	1,100,000	$7.01	$7.71M	6.5%	Form 4
Feb 4, 2025 – Feb 5, 2025	Douglas Barry General Counsel	SoldNo plan 2 parts	5,330	$3.07 average	16K	7.5%	Form 4
Feb 4, 2025 – Feb 5, 2025	Daniella Beckman Chief Financial Officer	SoldNo plan 2 parts	8,232	$3.07 average	25K	5.2%	Form 4
Feb 4, 2025 – Feb 5, 2025	Adam Crystal See Remarks	SoldNo plan 2 parts	14,283	$3.07 average	44K	8.3%	Form 4
Feb 4, 2025 – Feb 5, 2025	Barbara Weber Chief Executive Officer	SoldNo plan 2 parts	18,791	$3.07 average	58K	1.1%	Form 4
Nov 14, 2024 – Nov 18, 2024	Mace Rothenberg Director	Bought 2 parts	20,000	$3.70 average	74K	178%	Form 4
Nov 6, 2024 – Nov 7, 2024	Ecor1 Capital, LLC Large holder	SoldNo plan 3 parts	2,700,000	$3.13 average	$8.45M	20%	Form 4
Nov 6, 2024	Boxer Capital Management, LLC Large holder	SoldNo plan	3,080,000	$3.14	$9.67M	46%	Form 4

Nov 210b5-1 plan
Adam Crystal
President, R&D · sold 5,000 at avg $22.42
112K
4.1% of stake
Nov 210b5-1 plan
Jessica Newcomb
Principal Accounting Officer · sold 7,031 at avg $22.42
158K
12% of stake
Oct 110b5-1 plan
Adam Crystal
President, R&D · sold 27,000 at avg $24.47
661K
19% of stake
Sep 2210b5-1 plan
Jessica Newcomb
Principal Accounting Officer · sold 8,200 at avg $24.22
199K
12% of stake
Sep 110b5-1 plan
Adam Crystal
President, R&D · sold 27,000 at $22.37
604K
19% of stake
Aug 310b5-1 plan
Adam Crystal
President, R&D · sold 27,000 at avg $27.24
736K
19% of stake
Jul 110b5-1 plan
Adam Crystal
President, R&D · sold 27,000 at avg $29.59
799K
19% of stake
Jun 110b5-1 plan
Adam Crystal
President, R&D · sold 27,000 at avg $22.88
618K
19% of stake
May 110b5-1 plan
Adam Crystal
President, R&D · sold 27,000 at avg $21.22
573K
19% of stake
Apr 1510b5-1 plan
Adam Crystal
President, R&D · sold 38,460 at $25.00
962K
25% of stake
Apr 110b5-1 plan
Adam Crystal
President, R&D · sold 27,000 at $21.20
572K
19% of stake
Mar 2510b5-1 plan
Adam Crystal
President, R&D · sold 12,000 at $20.11
241K
9.6% of stake
Mar 510b5-1 plan
Adam Crystal
President, R&D · sold 20,251 at $15.00
304K
15% of stake
Feb 2510b5-1 plan
Adam Crystal
President, R&D · sold 54,345 at $12.77
694K
29% of stake
Feb 3No plan
Daniella Beckman
Chief Financial Officer · sold 10,317 at avg $12.27
127K
5.3% of stake
Feb 3No plan
Barbara Weber
Director, Executive Chair · sold 30,519 at avg $12.27
374K
1.8% of stake
Feb 3No plan
Adam Crystal
President, R&D · sold 18,452 at avg $12.27
226K
9.0% of stake
Oct 23, 2025No plan
TRV GP IV, LLC
Large holder · sold 477,401 at $10.15
$4.85M
3.4% of stake
Sep 25, 2025No plan
TRV GP IV, LLC
Large holder · sold 500,000 at $8.02
$4.01M
3.5% of stake
Sep 16, 2025No plan
TRV GP IV, LLC
Large holder · sold 363,541 at $7.04
$2.56M
2.5% of stake
Sep 5, 2025 – Sep 8, 2025No plan
TRV GP IV, LLC
Large holder · sold 729,365 at avg $7.00
$5.11M
4.7% of stake
Aug 22, 2025No plan
Third Rock Ventures GP IV, L.p.
Large holder · sold 302,194 at $7.00
$2.12M
1.9% of stake
Aug 19, 2025No plan
Third Rock Ventures GP IV, L.p.
Large holder · sold 1,100,000 at $7.01
$7.71M
6.5% of stake
Feb 4, 2025 – Feb 5, 2025No plan
Douglas Barry
General Counsel · sold 5,330 at avg $3.07
16K
7.5% of stake
Feb 4, 2025 – Feb 5, 2025No plan
Daniella Beckman
Chief Financial Officer · sold 8,232 at avg $3.07
25K
5.2% of stake
Feb 4, 2025 – Feb 5, 2025No plan
Adam Crystal
See Remarks · sold 14,283 at avg $3.07
44K
8.3% of stake
Feb 4, 2025 – Feb 5, 2025No plan
Barbara Weber
Chief Executive Officer · sold 18,791 at avg $3.07
58K
1.1% of stake
Nov 14, 2024 – Nov 18, 2024
Mace Rothenberg
Director · bought 20,000 at avg $3.70
74K
178% of stake
Nov 6, 2024 – Nov 7, 2024No plan
Ecor1 Capital, LLC
Large holder · sold 2,700,000 at avg $3.13
$8.45M
20% of stake
Nov 6, 2024No plan
Boxer Capital Management, LLC
Large holder · sold 3,080,000 at $3.14
$9.67M
46% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TNGX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with TNGX

CompareIntrinsic value

QTTBQ32 Bio Inc.

$8.97+2.40%60

AQSTAquestive Therapeutics Inc.

$3.80-2.06%10

XLOXilio Therapeutics, Inc.

$8.71+0.35%40

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

GOSSGossamer Bio Inc.

$9.40+1.29%10

OCULOcular Therapeutix Inc.

$7.14+4.69%10

NKTRNektar Therapeutics Inc.

$38.48+1.91%25

AYTUAytu BioPharma Inc.

$1.92-0.52%48

Held by ETFs

TNGX is in 53 US ETFs. The largest of them, with TNGX's weight in each:

Spot a number that looks wrong? Check it in TNGX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TNGX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.